Clinical EfficacyQRX003 produced complete skin clearing and elimination of severe itching in a pediatric Whole Body study subject, indicating a strong symptomatic benefit that supports potential clinical impact in Netherton Syndrome.
Financing And RunwayCompleted financing that raised $16.5 million upfront with potential additional payments up to $104.5 million extends the company’s cash runway to advance late-stage studies and regulatory preparations.
Formulation And DeliverySuccessful formulation work achieved targeted topical drug loading with both a cream formulation and a dermal patch, offering flexible local delivery options that could improve treatment effectiveness and patient adherence.